The beneficial effect of targeting pro-inflammatory cytokines is testified to by the clinical efficacy of monoclonal antibodies in biological drugs working against TNF-α, IL-6 or IL-1β in RA patients, whilst in AS and PsA, along with TNF-α, IL-12/23 and IL-17 axis is involved [38,39]. Here, IL6 is linked to rheumatoid arthritis.